Literature DB >> 1204253

Immune reactions in acute viral hepatitis.

D I Newble, K T Holmes, A G Wangel, I J Forbes.   

Abstract

Serial studies of PHA-induced lymphocyte transformation, serum autoantibodies, immunoglobulins and complement were performed in seventeen patients with hepatitis A and nine patients with hepatitis B. In both types of hepatitis PHA-induced transformation was markedly impaired during the 1st week after the onset of jaundice and there was less marked but prolonged impairment for a further period of 6-10 weeks. A group of eleven subjects with a previous history of hepatitis had values which were similar to those of healthy persons. Serum from patients with hepatitis A and hepatitis B contains an inhibitor of lymphocyte response to PHA. The inhibitor depresses the function of both patients' and normal lymphocytes and is only detectable during the acute phase of the illness. Washing lymphocytes free from autologous serum did not restore the PHA response to normal but the markedly impaired response present during the first 2 weeks of the illness was improved. A serum factor or factors may therefore be responsible for at least part of the impaired response of lymphocytes to PHA during the acute phase of hepatitis but does not appear to account for the more prolonged impairment of the PHA response. The protracted lymphocyte defect is possibly induced by hepatitis virus. The incidence of autoantibodies and the changes in immunoglobulin levels were similar to those reported by other workers.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1204253      PMCID: PMC1538174     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Relation between Australia antigen and autoimmune hepatitis.

Authors:  H Popper; I R Mackay
Journal:  Lancet       Date:  1972-05-27       Impact factor: 79.321

2.  Serum immunoglobulins, complement component levels and autoantibodies in liver disease.

Authors:  R A Thompson; R Carter; R P Stokes; A M Geddes; J A Goodall
Journal:  Clin Exp Immunol       Date:  1973-07       Impact factor: 4.330

3.  Lymphocyte transformation and hepatitis. I. Impairment of thymidine incorporation and DNA polymerase activity.

Authors:  S S Agarwal; B S Blumberg; B J Gerstley; W T London; I Millman; A I Sutnick; L A Loeb
Journal:  Proc Soc Exp Biol Med       Date:  1971-09

4.  Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.

Authors:  D Doniach; I M Roitt; J G Walker; S Sherlock
Journal:  Clin Exp Immunol       Date:  1966-07       Impact factor: 4.330

5.  Inhibition of PHA-stimulated lymphocyte transformation by plasma from patients with advanced alcoholic cirrhosis.

Authors:  C C Hsu; C M Leevy
Journal:  Clin Exp Immunol       Date:  1971-05       Impact factor: 4.330

6.  Complement levels in acute infectious hepatitis and serum hepatitis.

Authors:  J C Kosmidis; L K Leader-Williams
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

7.  Serum immunoglobulin levels in Australia antigen positive and Australia antigen negative hepatitis.

Authors:  C J Peters; K M Johnson
Journal:  Clin Exp Immunol       Date:  1972-07       Impact factor: 4.330

8.  Patterns of immunoglobulins in acute viral hepatitis: relation to hepatitis-associated antigen.

Authors:  S Iwarson; J Holmgren
Journal:  J Infect Dis       Date:  1972-02       Impact factor: 5.226

9.  Microtechnique for quantitative evaluation of in vitro lymphocyte transformation.

Authors:  U Junge; J Hoekstra; L Wolfe; F Deinhardt
Journal:  Clin Exp Immunol       Date:  1970-09       Impact factor: 4.330

10.  Serum hepatitis antigen (SH): rapid detection by high voltage immunoelectroosmophoresis.

Authors:  A M Prince; K Burke
Journal:  Science       Date:  1970-08-07       Impact factor: 47.728

View more
  12 in total

1.  Clinical significance of immunopathological findings in patients with post-pericardiotomy syndrome. II. The significance of serum inhibition and rosette inhibitory factors.

Authors:  B Maisch; P Schuff-Werner; P A Berg; K Kochsiek
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

2.  Lymphocyte transformation test with liver-specific protein and phytohaemagglutinin in patients with liver disease.

Authors:  K Thestrup-Pedersen; K Ladefoged; P Andersen
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

3.  Interleukin-1 production in acute viral hepatitis.

Authors:  C Müller; I Gödl; R Ahmad; H M Wolf; J W Mannhalter; M M Eibl
Journal:  Arch Dis Child       Date:  1989-02       Impact factor: 3.791

4.  Cell-mediated immunity during natural measles infection.

Authors:  H C Whittle; J Dossetor; A Oduloju; A D Bryceson; B M Greenwood
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

5.  Suppression of immunoglobulin production of rat lymphocytes by bile acids.

Authors:  K Yamada; B O Lim; M Sugano
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

6.  The liver as a barrier against antigens in viral hepatitis infection.

Authors:  P R Lorenz
Journal:  Naturwissenschaften       Date:  1978-12

7.  Effects of bile acids and lectins on immunoglobulin production in rat mesenteric lymph node lymphocytes.

Authors:  B O Lim; K Yamada; M Sugano
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

8.  Autoantibodies detected in rabbits hyperimmunized with group A, C, and G streptococcal vaccines.

Authors:  D Onică; F Mihalcu; R Lenkei; M Gherman; M Tudor
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Serum inhibitory factors (SIF) in patients with acute and chronic hepatitis and their clinical significance.

Authors:  N Brattig; P A Berg
Journal:  Clin Exp Immunol       Date:  1976-07       Impact factor: 4.330

10.  Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes.

Authors:  Y Haga; M A Tempero; D Kay; R K Zetterman
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.